Globus Medical, Inc. (GMED)
Stock Price Chart
Key Info
| Market Cap | 5.28B |
| Revenue (ttm) | 747.38M |
| Net Income (ttm) | 88.95M |
| Shares Out | 75.33M |
| EPS (ttm) | 0.88 |
| PE Ratio | 61.43 |
| Forward PE | 52.63 |
| Dividend | n/a |
| Dividend Yield | n/a |
Stock Quote
| Trading Day | Aug 11, 2020 |
| Last Price | $54.06 |
| Previous Close | $55.33 |
| Change ($) | -1.27 |
| Change (%) | -2.30% |
| Day's Open | 55.49 |
| Day's Range | 53.93 - 55.50 |
| Day's Volume | 1,141,850 |
| 52-Week Range | 33.41 - 60.15 |
More Stats
| Market Cap | 5.28B |
| Enterprise Value | 4.97B |
| Earnings Date (est) | Nov 10, 2020 |
| Ex-Dividend Date | n/a |
| Shares Outstanding | 75.33M |
| Float | 74.20M |
| EPS (basic) | 0.9 |
| EPS (diluted) | 0.88 |
| FCF / Share | 1.18 |
| Dividend | n/a |
| Dividend Yield | n/a |
| Earnings Yield | 1.63% |
| FCF Yield | 2.18% |
| Payout Ratio | n/a |
| Shares Short | 4.51M |
| Short Ratio | 3.09 |
| Short % of Float | 7.02% |
| Beta | 0.96 |
| PE Ratio | 61.43 |
| Forward PE | 52.63 |
| P/FCF Ratio | 45.79 |
| PS Ratio | 7.07 |
| PB Ratio | 4.16 |
| Revenue | 747.38M |
| Operating Income | 94.93M |
| Net Income | 88.95M |
| Free Cash Flow | 115.41M |
| Net Cash | 316.74M |
| Net Cash / Share | 3.24 |
| Gross Margin | 81.00% |
| Operating Margin | 12.70% |
| Profit Margin | 11.90% |
| FCF Margin | 15.44% |
| ROA | 4.37% |
| ROE | 6.78% |
| ROIC | 9.60% |
Analyst Summary
Analyst Consensus: Buy
Financial Performance
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 785 | 713 | 636 | 564 | 545 | 474 | 434 | 386 | 331 | 288 |
| Revenue Growth | 10.15% | 12.11% | 12.76% | 3.53% | 14.84% | 9.19% | 12.56% | 16.45% | 15.02% | - |
| Gross Profit | 605 | 554 | 486 | 429 | 412 | 364 | 334 | 311 | 263 | 234 |
| Operating Income | 172 | 169 | 162 | 154 | 172 | 138 | 102 | 115 | 97.36 | 87.69 |
| Net Income | 155 | 156 | 107 | 104 | 113 | 92.49 | 68.61 | 73.83 | 60.78 | 54.46 |
| Shares Outstanding | 99.15 | 97.88 | 96.24 | 95.65 | 95.05 | 94.23 | 92.65 | 89.61 | 88.11 | 88.93 |
| Earnings Per Share | 1.52 | 1.54 | 1.10 | 1.08 | 1.17 | 0.97 | 0.73 | 0.80 | 0.67 | 0.60 |
| EPS Growth | -1.3% | 40% | 1.85% | -7.69% | 20.62% | 32.88% | -8.75% | 19.4% | 11.67% | - |
| Operating Cash Flow | 172 | 182 | 159 | 148 | 124 | 79.17 | 93.47 | 76.52 | 76.41 | 71.29 |
| Capital Expenditures | -70.75 | -54.70 | -51.30 | -40.91 | -50.76 | -24.75 | -23.68 | -24.68 | -22.49 | -12.30 |
| Free Cash Flow | 101 | 127 | 108 | 107 | 73.25 | 54.42 | 69.79 | 51.84 | 53.92 | 58.99 |
| Cash & Equivalents | 311 | 340 | 374 | 291 | 307 | 252 | 239 | 212 | 143 | 112 |
| Total Debt | - | - | - | - | - | - | - | - | - | 5.25 |
| Net Cash / Debt | 311 | 340 | 374 | 291 | 307 | 252 | 239 | 212 | 143 | 106 |
| Assets | 1,532 | 1,301 | 1,079 | 928 | 834 | 704 | 566 | 447 | 329 | 267 |
| Liabilities | 130 | 115 | 111 | 95.56 | 119 | 118 | 93.94 | 60.63 | 46.91 | 38.38 |
| Book Value | 1,402 | 1,186 | 968 | 832 | 715 | 585 | 472 | 387 | 282 | 228 |
Company Profile
Company Details
| Full Name | Globus Medical, Inc. |
| Country | United States |
| Employees | 2,000 |
| CEO | David M. Demski |
Stock Information
| Ticker Symbol | GMED |
| Stock Exchange | New York Stock Exchange |
| Sector | Healthcare |
| Industry | Medical Appliances & Equipment |
| Unique Identifier | NYSE: GMED |
| IPO Date | August 3, 2012 |
Description
Globus Medical, Inc., a medical device company, focuses on the development and commercialization of implants that heal patients with musculoskeletal disorders. Its spine product portfolio includes a range of implant and surgical approach options that can be used to treat degenerative, deformity, tumor, and trauma conditions affecting the spine from the occiput to the sacrum. The company also offers products for the treatment of orthopedic trauma, including fracture plates, compression screws, intramedullary nails, and external fixation systems; and regenerative biologic products, such as allografts and synthetic alternatives that are adjunctive treatments used in combination with stabilizing implant hardware. In addition, it provides motion preservation technologies, such as dynamic stabilization, total disc replacement and interspinous distraction devices, and interventional pain management solutions to treat vertebral compression fractures; imaging, navigation, and robotic assisted surgery technology solutions; and hip and knee joint solutions, as well as distributes human cell, tissue, and cellular and tissue based products. Further, the company offers expandable spacer products, which include RISE, RISE-L, CALIBER, CALIBER-L, ALTERA, ELSA, ELSA-ATP, SABLE, MAGNIFY, MAGNIFY-S, FORTIFY, and XPand; CREO thoracolumbar stabilization platform that offers instruments and implants for treating pathologies; CREO MIS and CREO MCS, options designed for less invasive surgery and minimal muscle disruption; CREO Derotation and CREO Rod Link Reducer systems, which help to streamline various derotation maneuvers for deformity correction; CREO Addition that provides a range of connectors; and CREO Fenestrated, a cement augmented pedicle screw system for patients with advanced stage tumors and limited life expectancy, as well as QUARTEX, an occipito-cervico-thoracic stabilization system. Globus Medical, Inc. was founded in 2003 and is headquartered in Audubon, Pennsylvania.